|
MechanismATP synthase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-label Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:
What is the safety profile of JYP0035 when administered to these patients?
How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.
An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are:
The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis.
The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis.
Participants will:
Be treated with either a low-dose or high-dose of JYP0061.
Undergo efficacy and safety evaluations as stipulated in the trial protocol.
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are:
Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment.
Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
100 Clinical Results associated with Guangzhou JOYO Pharma Co., Ltd
0 Patents (Medical) associated with Guangzhou JOYO Pharma Co., Ltd
100 Deals associated with Guangzhou JOYO Pharma Co., Ltd
100 Translational Medicine associated with Guangzhou JOYO Pharma Co., Ltd